BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
340.38
-9.62 (-2.75%)
Jan 30, 2026, 4:00 PM EST - Market closed
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.41B in the quarter ending September 30, 2025, with 41.00% growth. This brings the company's revenue in the last twelve months to $4.97B, up 49.92% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of $3.81B with 54.96% growth.
Revenue (ttm)
$4.97B
Revenue Growth
+49.92%
P/S Ratio
7.40
Revenue / Employee
$452,062
Employees
11,000
Market Cap
37.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.34B |
| Incyte | 4.81B |
| Genmab | 3.85B |
| BioNTech SE | 3.70B |
| argenx SE | 3.68B |
| Alnylam Pharmaceuticals | 3.21B |
| Royalty Pharma | 2.35B |
| Moderna | 2.23B |
ONC News
- 19 days ago - BeOne Medicines AG (ONC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 19 days ago - BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 26 days ago - ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA - Business Wire
- 5 weeks ago - BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma - Business Wire
- 7 weeks ago - Senhwa Biosciences and BeOne Medicines Announces a Clinical Supply Agreement to Address the Challenge of Cold Tumors - PRNewsWire
- 7 weeks ago - BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia - Business Wire
- 2 months ago - Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies - Business Wire